Navidea Biopharmaceuticals Inc. is much closer to catching a lifeline: The Dublin biotech company now has a definitive asset purchase agreement from Cardinal Health Inc. for rights to its only drug on the market – a deal that could extricate it from a legal stranglehold with a creditor.
Both boards for Navidea (NYSEMKT:NAVB) and Dublin health-care giant Cardinal (NYSE:CAH) have approved the deal: It calls for Navidea to sell North American rights to the radioactive cancer diagnostic aid Lymphoseek…
Navidea Biopharmaceuticals Inc. is much closer to catching a lifeline: The Dublin biotech company now has a definitive asset purchase agreement from Cardinal Health Inc. for rights to its only drug on the market – a deal that could extricate it from a legal stranglehold with a creditor.
Both boards for Navidea (NYSEMKT:NAVB) and Dublin health-care giant Cardinal (NYSE:CAH) have approved the deal: It calls for Navidea to sell North American rights to the radioactive cancer diagnostic aid Lymphoseek…